As of Apr 29
| -0.25 / -0.45%|
The 33 analysts offering 12-month price forecasts for Novo Nordisk have a median target of 61.59, with a high estimate of 73.80 and a low estimate of 44.42. The median estimate represents a +10.40% increase from the last price of 55.79.
The current consensus among 34 polled investment analysts is to Buy stock in Novo Nordisk. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.